Clinical characteristics of cervical cancer in patients infected with human immunodeficiency virus

   Background. Infection caused by human immunodeficiency virus (HIV) is a slowly developing anthroponosis with a long course and a variety of clinical manifestations, which finally results in acquired immunodeficiency syndrome (AIDS). Over the past 4 decades, the HIV / AIDS pandemic has been considered as one of the world’s most serious public health problems. Globally, there were approximately 38 million people living with HIV in 2022; 53 % of them were women. The number of HIV-infected patients living in Russia reaches 1,168,000. The incidence and prevalence of HIV infection
varies across different regions of Russia. High prevalence of cervical cancer usually correlates with HIV prevalence, which is associated with the long-term and aggressive persistence of human papillomavirus (HPV) in HIV patients. HIV co-infection is believed to be the main risk factor for HPV-related precancerous lesions to the cervical epithelium and their rapid progression to invasive cancer.

   Aim. To analyze risk factors for poor prognosis in HIV-infected patients with HPV.

   Materials and methods. This study included 15 HIV-infected patients with cervical cancer treated in Novosibirsk Regional Clinical Oncology Dispensary or Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of Russia between 2016 and 2021.

   Results. Median age of the patients was 38 years; all of them were HPV-positive. Their viral load was >400 copies / mL and baseline CD4+ cell count ≥350 cells / mL. All patients were diagnosed with AIDS, given the presence of HPV infection. During the therapy for cervical cancer, patients also received combination antiretroviral treatment, including Lamivudine Advanced at a dose of 300 mg / day. Ten patients received comprehensive treatment, while 8 patients received chemoradiotherapy.

   Conclusion. Given the more aggressive course of cervical cancer in HIV-infected patients, their treatment plan should be developed by a multidisciplinary team, including an infectious disease specialist, clinical pharmacologist, radiotherapist, and gynecological oncologist. Such patients should receive maximal antitumor treatment, as well as intensive antiretroviral therapy. HIV-positive women with cervical cancer require special attention to ensure treatment completion and to optimize long-term outcomes.

1. Sung H., Ferlay J., Siegel R. L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49.

2. Situtation with cancer care in Russia in 2021. Ed. by A. D. Kaprin, V. V. Starinskiy, A. O. Shakhzodova. Moscow, 2022. (In Russ.)

3. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS Statistics – Fact Sheet. Accessed August 5, 2021.

4. Clifford G. M., Tully S., Franceschi S. Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer. Clin Infect Dis 2017; 64 (9): 1228–35. DOI: 10.1093/cid/cix135

5. Liu G., Sharma M., Tan N., Barnabas R. V. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018; 32 (6): 795–808. DOI: 10.1097/QAD.0000000000001765

6. Josep B., Chiramana H. 2004. Extensive subcutaneous metastasis from squamous cell carcinoma of the cervix in patient with HIV. Int J Gynecol Cancer 2004; 14 (1): 176–7. URL: https://pubmed.ncbi.nlm.nih.gov/14764050/

7. Montaño M. A., Chagomerana M. B., Borok M. et al. Impact of antiretroviral therapy on cancer treatment outcomes among people living with HIV in low- and middle-income countries: a systematic review. Curr HIV/AIDS Rep 2021; 18 (2): 105–16. DOI: 10.1007/s11904-021-00542-5

8. Gurram L., Mohanty S., Chopra S. et al. Outcomes of cervical cancer in HIV-positive women treated with radiotherapy at a tertiary care center in India. JCO Global Oncol 2022; 8: e2100312. DOI: 10.1200/GO.21.00312

9. Yurin O. G., Efremova O. S. European and American guidelines for the treatment of HIV infection. Meditsinskiy sovet = Medical Council 2017; (4): 67–72. (In Russ.)

10. Elion R. A., Witt M. D. Nucleoside and nucleotide reverse transcriptase inhibitors in the treatment of HIV: focus on efficacy. 2003. Medscape. Available at: https://www.researchgate.net/publication/8885424_Extensive_subcutaneous_metastasis_from_squamous_cell_carcinoma_of_the_cervix_in_patient_with_HIV

11. Treatment of HIV-infection: 2011. Ed. by C. Hoffmann, J. K. Rockstroh. Moscow, 2012. P. 91. (In Russ.)

12. Einstein M. H., Ndlovu N., Lee J. et al. Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium. Gynecol Oncol 2019; 153: 20–5. DOI: 10.1016/j.ygyno.2019.01.023

13. Simonds H. M., Neugut A. I., Jacobson J. S. HIV status and acute hematologic toxicity among patients with cervix cancer undergoing radical chemoradiation. Int J Gynecol Cancer 2015; 25 (5): 884–90. DOI: 10.1097/IGC.0000000000000441